Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies
The burgeoning pipeline of chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) in multiple myeloma was on full display at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. A bispecific antibody also made its debut in this busy therapeutic field.
Opioid Use Following Thoracoscopic Surgery in Early-Stage Lung Cancer
In a study reported in a research letter in JAMA Oncology, Stephanie Tuminello, MPH, and colleagues found that video-assisted thoracoscopic surgery (VATS) was less likely than open resection to be associated with long-term opioid use in patients undergoing surgery for early-stage lung cancer.
In Vitro and Ex Vivo Activity of Gentian Violet in Cutaneous T-Cell Lymphoma
As reported in JAMA Dermatology, Jianqiang Wu, MD, PhD, and Gary S. Wood, MD, found that the widely available nonprescription topical antimicrobial agent gentian violet has potent activity against cutaneous T-cell lymphoma (CTCL) in studies in vitro and ex vivo.
Breast Cancer Surgical Terminology Should Be Updated to Reflect Modern Medical Practice
Breast cancer is a microscopic disease, with most patients presenting with “localized” stage I to III disease, for which they are offered curative-intent surgery...
Dealing With the Challenges Presented by the Parenteral Opioid Shortage
The opioid drug problem in the United States is a crisis, with unprecedented numbers of overdose deaths. The reaction to this has resulted in...
Allen Lichter: The Potential of Value-Based Prescribing in Oncology
Karen Reckamp: PACIFIC Trial of Durvalumab in Stage III Unresectable NSCLC
Damien Hansra: Breast Cancer Surgical Terminology Update
Thomas Witzig: Essential Elements of an Effective Clinical Trials System
Fred Hirsch: Progress With ALK Inhibitors
More Top Stories
ASH Research Collaborative Established to Accelerate Progress in Hematology
THE AMERICAN SOCIETY of Hematology (ASH) has established the ASH Research Collaborative, a mission-focused nonprofit organization that will foster collaborative partnerships to accelerate progress in hematology with the goal of improving the lives of people affected by blood diseases. “The...
Hospitalizations in Patients With Prostate Cancer on Medicare
In a retrospective analysis reported in the Journal of Oncology Practice, Parikh et al found that more than one-quarter of hospitalizations in Medicare patients with prostate cancer were potentially avoidable. Study Details The study involved 99 evaluable patients in the Mount Sinai Health System ...
New JOP Article Highlights Challenges Oncologists Face Due to a Lack of Interoperability, and How CancerLinQ® Can Help
A new article in the Journal of Oncology Practice (JOP)1 looks at how ASCO’s commitment to CancerLinQ® can lead to improvements in the interoperability of electronic health records (EHRs). The article, by Wendy S. Rubinstein, MD, PhD, FACP, FACMG, Deputy Medical Director of CancerLinQ LLC,...
Breast Cancer Surgical Terminology Should Be Updated to Reflect Modern Medical Practice
BREAST CANCER is a microscopic disease, with most patients presenting with “localized” stage I to III disease, for which they are offered curative-intent surgery often accompanied by radiation therapy, chemotherapy, and hormonal therapy. More accurately, we now know that patients with localized...
ERG Gene Variations and Risk of ALL in Hispanic Children
Scientists have identified genetic variations in a fourth gene that are associated with an increased risk of acute lymphoblastic leukemia (ALL) in Hispanic children. These findings were published by Qian et al in Blood. The gene is ERG, a transcription factor that is also...
Living My Best Life
Five years ago, I was living my dream life. I was under contract as a commentator on Fox News, which necessitated commuting weekly from my home in Los Angeles to New York, and was building a new home in Palm Springs with my partner, Matt Lashey. Not only was my career and personal life going well,...
2019 GU Cancers Symposium: TIVO-3: Tivozanib vs Sorafenib in Refractory Advanced Renal Cell Carcinoma
The TIVO-3 trial was conducted to confirm progression-free survival results from the TIVO-1 trial, which found an improvement in median progression-free survival in patients with metastatic renal cell carcinoma treated with tivozanib vs sorafenib. Findings from TIVO-3 were presented by...
Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents
Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib
Zaida Morante, MD, on Triple-Negative Breast Cancer: Delaying Adjuvant Chemotherapy
John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome
